Press Releases

The Global Alzheimer’s Platform Foundation (GAP) thanks the First Lady for the grace and dignity she showed before and after President Carter’s term, and even more so these past six months after bravely announcing her dementia diagnosis. We join many around the world mourning her loss while acknowledging her quiet, positive impact over her 96 years.  […]

We applaud First Lady Jill Biden and the White House Gender Policy Council on the first ever initiative on Women’s Health Research, with a focus on ‘engaging the scientific, private sector, and philanthropic communities’. GAP is committed to ensuring that clinical research includes all people, and that includes ensuring that women are equally represented. We […]

Today, the US Senate confirmed President Biden’s nominee for National Institutes of Health (NIH) Director, Monica Bertagnolli, MD, who will lead the country’s top medical research institute. “We are thrilled that the US Senate has confirmed Dr. Monica Bertagnolli as the new Director of the NIH, as she is an esteemed leader with an impressive career […]

Washington D.C., Oct 23, 2023- Global Alzheimer’s Platform Foundation, (GAP) is pleased to share that new data from the ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, will be shared by study partner Dr. Robin Wolz, of IXICO, at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference. The data will be presented at Symposium […]

Revolutionary Studies, Record Breaking Collaboration, and Promising News on Biomarker Studies Top the Charts at AAIC   Washington D.C., Aug 31, 2023— Researchers and leaders from the Global Alzheimer’s Platform Foundation® (GAP) assembled with the world’s leading Alzheimer’s researchers, patient advocates, and clinicians at the annual Alzheimer’s Association International Conference (AAIC). From the memorable week, […]

The FDA’s approval comes following the recommendation of an FDA advisory committee, which voted unanimously for Leqembi’s full approval earlier this month WASHINGTON, DC, July 6, 2023 — Following a decision from the U.S. Food and Drug Administration (FDA) granting full traditional approval to Leqembi, a disease-modifying Alzheimer’s treatment from Eisai, Global Alzheimer’s Platform Foundation® (GAP) […]

Bio-Hermes won’t just change Alzheimer’s research and diagnostics. It has the potential to save and change lives. WASHINGTON, DC (June 14, 2023) — Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools typically used to detect the disease, like a PET […]

Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation: (WASHINGTON, DC, JUNE 12) – “Last week, I was proud to participate in the open public hearing session at the Food and Drug Administration (FDA)’s Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting in support of full approval of […]

June 8, 2023 Mrs. Rosalynn Carter c/o The Carter Center 453 John Lewis Freedom Parkway NE Atlanta, GA 30307-1406 Dear Mrs. Carter: I read with heartfelt interest the news announcing your dementia diagnosis. Thank you for sharing this news so bravely and publicly. Receiving a dementia or Alzheimer’s diagnosis, and how that news impacts a […]

News that the U.S. Centers for Medicare and Medicaid Services (CMS) will provide broader coverage for Alzheimer’s treatments lacks specifics; unclear if rural and non-hospital based physicians can participate Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation: (WASHINGTON, DC, JUNE 1) — “It’s too early to celebrate. The U.S. Centers […]

Americans want Congress and the president to step in if CMS doesn’t change its restrictive coverage policy. WASHINGTON (May 23, 2023) — Nearly nine in ten voters favor (87% favor, 77% strongly favor) requiring Medicare to cover the cost of FDA-approved drugs that can slow the progression of Alzheimer’s disease, according to a new poll […]

“GAP strongly encourages ICER to revamp its model to accurately reflect Leqembi’s benefits and what matters most to patients and their families” For immediate release: Washington, D.C. (March 17, 2023) — Joining other Alzheimer’s advocates, experts and researchers, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer provided written comments as part of the Institute for […]

“Today, the Veterans Health Administration (VA) demonstrated enormous leadership and concern for the health of veteran’s fighting Alzheimer’s disease with its decision to cover the cost of Leqembi.  Our veterans battled for us, and the VA is now giving their patients new therapies to battle Alzheimer’s.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: […]

Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 27, 2023) — “On behalf of the of the thousands of trial participants, clinicians and researchers who are part of the Global Alzheimer’s Platform Foundation (GAP) network, we want to thank and honor Dr. Billy Dunn for his leadership and scientific contributions, which […]

“CMS’s latest decision on disease-modifying therapies for Alzheimer’s patients is effectively a coverage denial for this entire class of drugs, and patients will needlessly die as a result of it.” Statement by Global Alzheimer’s Platform Foundation® President John Dwyer: Washington, D.C. (Feb. 23, 2023) — “Once again, the Centers for Medicare and Medicaid Services (CMS) […]

The Global Alzheimer’s Platform Foundation’s® (GAP) 2022 Citizen Scientist Award recipients include the first husband-and-wife volunteer team, an Alzheimer’s advocate who champions participation in prevention studies, and a Parkinson’s disease clinical trial participant who volunteers in research studies to find hope after diagnosis  WASHINGTON, DC (Feb. 22, 2023) — Today, the Global Alzheimer’s Platform Foundation […]

The Global Alzheimer’s Platform Foundation® adds Lammert Albers to its team in the role of chief commercial officer; he joins GAP with leadership experience in growing clinical trial and life science technology companies WASHINGTON, DC (Feb. 21, 2023) — The Global Alzheimer’s Platform Foundation (GAP) welcomes Lammert Albers to its leadership team. Lammert has successfully […]

“With this approval, it is incumbent on Center for Medicare and Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and the drug’s sponsors to offer this life-changing therapy to patients quickly, while prioritizing access and economic fairness.” Statement attributed to Global Alzheimer’s Platform Foundation President John Dwyer: Washington, D.C. (Jan. 6, 2023) — We applaud the Food […]

Washington, DC — December 23, 2022–Appropriations bills are not simply about funding. They are about people. That is why we are grateful that Congress prioritized funding for accelerated and disruptive Alzheimer’s disease research in the 2023 Omnibus Appropriations Bill. Increases in funding for the Advanced Research Projects Agency for Health (ARPA-H) and the National Institutes […]

Washington, DC — December 23, 2022–The Institute for Clinical and Economic Review (ICER) has again failed in its attempt to value the benefit provided by a new, life-improving Alzheimer’s treatment, threatening millions of Americans who are living with Alzheimer’s disease. The report, “Beta-Amyloid Antibodies for Early Alzheimer’s Disease,” released yesterday, advances an analytical framework that […]

Washington, D.C. (Nov. 30, 2022) – “Following the positive, detailed results from Eisai on lecanemab, a monoclonal antibody therapy for the treatment of Alzheimer’s, there is every reason for the Alzheimer’s community to have optimism today. Thanks to the unwavering commitment of Eisai, its clinical trial partners, and most importantly, the people who participated in […]

The Global Alzheimer’s Platform Foundation (GAP) closed its ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, which is powered to measure more than 36 technologies’ effectiveness across three stages of Alzheimer’s disease, while drawing from all races and ethnic groups affected by the disease. WASHINGTON, DC (Nov. 15, 2022) — In 18 months, the Global […]

The Global Alzheimer’s Platform Foundation (GAP) is grateful for Roche’s efforts and leadership on the gantenerumab study to treat Alzheimer’s disease. We applaud Roche’s robust and well-designed study, and for holding to an ongoing commitment to research in this field. Every clinical study improves our understanding of Alzheimer’s disease, so this data will be of […]

WASHINGTON, DC, Oct. 5, 2022 — Today, the Global Alzheimer’s Platform Foundation (GAP) applauds and vigorously supports Congressmembers Vern Buchanan (R-FL) and Nanette Diaz Barragán (D-CA) for bringing forward a new bill to help ensure coverage of potentially life-saving drugs and new treatments for Medicare beneficiaries, including access to approved Alzheimer’s treatments. The bill — known as […]